Efficacy and tolerability of nimotuzumab in combination with chemotherapy in recurrent and metastatic squamous cell carcinoma of head and neck at a cancer center in Northern India

Conclusion: In this study, the combination of Nimotuzumab plus platinum/taxane based chemotherapy was active and well tolerated in Indian patients in R/M SCCHN. Addition of Nimotuzumab to chemotherapy had a response rate of 38.2% and median PFS of 5.2 months are strong arguments for clinically testing this combination.

Source: Indian Journal of Cancer - February 25, 2020 Category: Cancer & Oncology Authors: Abhishek Yadav Pankaj Goyal Chaturbhuj R Agrawal Sneha J Bothra Parveen Jain Kumardeep Dutta Choudhury Sunil Kumar Gupta Manish Sharma Rajat Bajaj Amitabh Upadhyay Prashanta Dash Dinesh C Doval Source Type: research